Journal article
Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses
The Journal of infectious diseases, Vol.224(8), pp.1372-1382
10/28/2021
DOI: 10.1093/infdis/jiab111
PMCID: PMC8861366
PMID: 33675226
Abstract
There are limited data regarding immunological correlates of protection for the modified vaccinia Ankara (MVA) smallpox vaccine.
A total of 523 vaccinia-naive subjects were randomized to receive 2 vaccine doses, as lyophilized MVA given subcutaneously, liquid MVA given subcutaneously (liquid-SC group), or liquid MVA given intradermally (liquid-ID group) 28 days apart. For a subset of subjects, antibody-dependent cellular cytotoxicity (ADCC), interferon-γ release enzyme-linked immunospot (ELISPOT), and protein microarray antibody-binding assays were conducted. Protein microarray responses were assessed for correlations with plaque reduction neutralization titer (PRNT), enzyme-linked immunosorbent assay, ADCC, and ELISPOT results.
MVA elicited significant microarray antibody responses to 15 of 224 antigens, mostly virion membrane proteins, at day 28 or 42, particularly WR113/D8L and WR101H3L. In the liquid-SC group, responses to 9 antigens, including WR113/D8L and WR101/H3L, correlated with PRNT results. Three were correlated in the liquid-ID group. No significant correlations were observed with ELISPOT responses. In the liquid-ID group, WR052/F13L, a membrane glycoprotein, correlated with ADCC responses.
MVA elicited antibodies to 15 vaccinia strain antigens representing virion membrane. Antibody responses to 2 proteins strongly increased and significantly correlated with increases in PRNT. Responses to these proteins are potential correlates of protection and may serve as immunogens for future vaccine development.
NCT00914732.
Details
- Title: Subtitle
- Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses
- Creators
- Sharon E Frey - Saint Louis UniversityJack T Stapleton - University of IowaZuhair K Ballas - University of IowaWendy L Rasmussen - University of IowaThomas M Kaufman - University of IowaTammy P Blevins - Saint Louis UniversityTravis L Jensen - EmmesD Huw Davies - University of California, IrvineMagdalena Tary-Lehmann - Cellular Technology Limited, Shaker Heights, Ohio, USAPaul Chaplin - Bavarian NordicHeather Hill - EmmesJohannes B Goll - EmmesDMID 09-0002 MVA Vaccine Study Group
- Resource Type
- Journal article
- Publication Details
- The Journal of infectious diseases, Vol.224(8), pp.1372-1382
- DOI
- 10.1093/infdis/jiab111
- PMID
- 33675226
- PMCID
- PMC8861366
- ISSN
- 0022-1899
- eISSN
- 1537-6613
- Grant note
- HHSN272200800003C / NIAID NIH HHS HHSN272200800007C / NIAID NIH HHS N01AI40098 / NIAID NIH HHS KL2 TR002317 / NCATS NIH HHS HHSN272201300023I / NIAID NIH HHS HHSN272200800004C / NIAID NIH HHS HHSN272201300022C / NIAID NIH HHS HHSN272200800008C / NIAID NIH HHS I01 BX000207 / BLRD VA TL1 TR002318 / NCATS NIH HHS HHSN272201300018I / NIAID NIH HHS HHSN272201300022I / NIAID NIH HHS HHSN272201300023C / NIAID NIH HHS HHSN272201300019I / NIAID NIH HHS HHSN272200800001C / NIAID NIH HHS HHSN27220130021I / NIAID NIH HHS HHSN272200800005C / NIAID NIH HHS HHSN272200800013C / NIAID NIH HHS HHSN272201300015I / NIAID NIH HHS TL1 TR000422 / NCATS NIH HHS UL1 TR002319 / NCATS NIH HHS HHSN272200800002C / NIAID NIH HHS HHSN272201300019C / NIAID NIH HHS HHSN272201500002C / NIAID NIH HHS HHSN272201300015C / NIAID NIH HHS UL1 RR024979 / NCRR NIH HHS KL2 TR000421 / NCATS NIH HHS UL1 TR000423 / NCATS NIH HHS
- Language
- English
- Date published
- 10/28/2021
- Academic Unit
- Microbiology and Immunology; Infectious Diseases; Immunology; Internal Medicine
- Record Identifier
- 9984297329402771
Metrics
12 Record Views